Astellas' ASP0113 Trial Failure Gives Merck's Prevymis Further CMV Boost

 
• By Sten Stovall
Basketball
Astellas And Vical Missed Targets In ASP0113 CMV Vaccine Trial • Source: Shutterstock

More from Strategy

More from Business